JP2010502603A - 血管形成を阻害し、血管形成関連疾患を処置する方法 - Google Patents

血管形成を阻害し、血管形成関連疾患を処置する方法 Download PDF

Info

Publication number
JP2010502603A
JP2010502603A JP2009526583A JP2009526583A JP2010502603A JP 2010502603 A JP2010502603 A JP 2010502603A JP 2009526583 A JP2009526583 A JP 2009526583A JP 2009526583 A JP2009526583 A JP 2009526583A JP 2010502603 A JP2010502603 A JP 2010502603A
Authority
JP
Japan
Prior art keywords
composition
colchicine
certain embodiments
nab
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009526583A
Other languages
English (en)
Japanese (ja)
Inventor
ニール ピー． デサイ，
ヴォン トリュー，
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2010502603A publication Critical patent/JP2010502603A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2009526583A 2006-08-31 2006-08-31 血管形成を阻害し、血管形成関連疾患を処置する方法 Pending JP2010502603A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/034365 WO2008027055A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Publications (1)

Publication Number Publication Date
JP2010502603A true JP2010502603A (ja) 2010-01-28

Family

ID=37763804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009526583A Pending JP2010502603A (ja) 2006-08-31 2006-08-31 血管形成を阻害し、血管形成関連疾患を処置する方法

Country Status (9)

Country Link
EP (1) EP2056812A1 (es)
JP (1) JP2010502603A (es)
CN (1) CN101568332A (es)
AU (1) AU2006347740A1 (es)
BR (1) BRPI0622006A2 (es)
CA (1) CA2662140A1 (es)
IL (1) IL197276A0 (es)
MX (1) MX2009002054A (es)
WO (1) WO2008027055A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013042684A1 (ja) * 2011-09-20 2015-03-26 国立大学法人 熊本大学 リポ蛋白を用いたα２−マクログロブリンの神経保護抑制効果抑止剤及び眼科用組成物
JP2017510584A (ja) * 2014-03-27 2017-04-13 インデナ エッセ ピ ア アモルファス形状のチオコルヒチン誘導体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUE048521T2 (hu) 2005-08-31 2020-08-28 Abraxis Bioscience Llc Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
PT2481409T (pt) 2007-03-07 2018-10-18 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
US20100297243A1 (en) 2009-04-15 2010-11-25 Desai Neil P Prion free nanoparticle compositions and methods of making thereof
WO2011076095A1 (en) * 2009-12-21 2011-06-30 Tty Biopharm Company Limited Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
LT2552438T (lt) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Hepatoceliulinės karcinomos gydymo būdai
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
LT2552415T (lt) 2010-03-29 2016-12-27 Abraxis Bioscience, Llc Vėžio gydymo būdai
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN105228612A (zh) 2013-03-12 2016-01-06 阿布拉科斯生物科学有限公司 治疗肺癌的方法
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EA202092187A1 (ru) 2015-06-29 2021-08-31 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения эпителиоидно-клеточных опухолей
JP2021528362A (ja) 2018-03-20 2021-10-21 アブラクシス バイオサイエンス， エルエルシー ｍＴＯＲ阻害剤およびアルブミンのナノ粒子の投与を介して中枢神経系障害を処置する方法
CN115003284A (zh) 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527371A (ja) * 2000-03-17 2003-09-16 インデナ・ソチエタ・ペル・アチオニ Ｎ−デアセチルチオコルヒチン誘導体及びそれを含有する医薬組成物
WO2004052401A2 (en) * 2002-12-09 2004-06-24 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
WO2005075418A2 (en) * 2004-02-03 2005-08-18 Indena S.P.A. N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1585548T1 (sl) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US6825236B2 (en) * 2003-04-14 2004-11-30 California Pacific Medical Center Colchicine derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527371A (ja) * 2000-03-17 2003-09-16 インデナ・ソチエタ・ペル・アチオニ Ｎ−デアセチルチオコルヒチン誘導体及びそれを含有する医薬組成物
WO2004052401A2 (en) * 2002-12-09 2004-06-24 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
WO2005075418A2 (en) * 2004-02-03 2005-08-18 Indena S.P.A. N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5009012233; ＴＲＩＥＵ　ＶＵＯＮＧ: ＰＲＯＣＥＥＤＩＮＧＳ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ　ＡＮＮＵＡＬ　ＭＥＥＴＩＮＧ Ｖ４７, 200604, Ｐ８９９ *
JPN5009012235; ＬＥＥ　Ｓ-Ｈ: ＡＲＣＨ　ＰＨＡＲＭ　ＣＨＥＭ　ＬＩＦＥ　ＳＯＣ Ｖ３３８　Ｎ１２, 2005, ５８２-５８９ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013042684A1 (ja) * 2011-09-20 2015-03-26 国立大学法人 熊本大学 リポ蛋白を用いたα２−マクログロブリンの神経保護抑制効果抑止剤及び眼科用組成物
JP2017510584A (ja) * 2014-03-27 2017-04-13 インデナ エッセ ピ ア アモルファス形状のチオコルヒチン誘導体

Also Published As

Publication number Publication date
WO2008027055A1 (en) 2008-03-06
IL197276A0 (en) 2009-12-24
EP2056812A1 (en) 2009-05-13
CA2662140A1 (en) 2008-03-06
AU2006347740A1 (en) 2008-03-06
CN101568332A (zh) 2009-10-28
MX2009002054A (es) 2009-05-01
BRPI0622006A2 (pt) 2011-12-20

Similar Documents

Publication Publication Date Title
JP2010502603A (ja) 血管形成を阻害し、血管形成関連疾患を処置する方法
US20080280987A1 (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
JP6685875B2 (ja) 治療薬の組み合わせおよび投与の様式ならびに併用療法
JP6882186B2 (ja) スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法
RU2451510C2 (ru) Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
RU2663687C2 (ru) Композиции наночастиц альбумина и паклитаксела
JP5725563B2 (ja) チオコルヒチン誘導体との組み合わせ療法
ES2428354T3 (es) Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
JP6677827B2 (ja) 眼科用医薬組成物
JP2016014073A (ja) 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子
BR112012030909A2 (pt) métodos de tratamento de câncer pancreático
JP2009507027A (ja) 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
KR20200051841A (ko) 나노입자 조성물의 혈관내 전달 및 그의 용도
JP2016512513A (ja) 小児充実性腫瘍の処置の方法
JP2021521173A (ja) 眼内薬物送達用の持続放出微粒子のための方法及び組成物
ES2315312T3 (es) Procedimiento y composiciones para el tratamiento de enfermedades del ojo.
KR20090057074A (ko) 혈관형성 억제 및 혈관형성 관련 질환 치료 방법
TW200810745A (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CA2917298C (en) Novel formulations of factor viia inhibitors and utility
RU2361615C2 (ru) Композиции и способы доставки фармакологических агентов
NZ714092B2 (en) Intravascular delivery of nanoparticle compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121012